Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763684 | 1.00 | TDP1 (0.54) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL9670841 | 0.98 | TDP1 (0.51) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL9668721 | 0.92 | IDO1 (0.57) | SIGMAR1IDO1FFAR1LMNA | |
| SCHEMBL8048487 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL7449325 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL7448881 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL7449055 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL626848 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL97368 | 0.86 | TDP1 (0.53) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 | |
| SCHEMBL96691 | 0.86 | TDP1 (0.53) | TDP1L3MBTL1MAPTRXFP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20210052575-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20200061056-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-20190167672-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20180318294-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-20180092907-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| US-20170071933-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-2753617-B9 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9539252-B2 | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160143905-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| EP-2753617-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9260420-B2 | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150045356-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
| WO-2013035892-A1 | PIPERAZINE- SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-14 | — | — | WO | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20170071933-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20160143905-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20180318294-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20210052575-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, SULT2A1, CYP4Z1 | TDP1 4353/4885L3MBTL1 3656/4885MAPT 422/4885 |
| US-20200061056-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20180092907-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20190167672-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
| US-20150045356-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | TDP1 4048/4885L3MBTL1 2967/4885MAPT 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.